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clear AKI-induced distant organ toxins? 
Earlier initiation of dialysis? Continu-
ous dialysis over intermittent? Improved 
membranes? Novel dialysis approaches, 
such as the renal assist device? Pharma-
cologic approaches to block deleteri-
ous pathways induced by AKI? A major 
opportunity clearly exists to improve 
our care of AKI patients, and studies on 
complex inter-organ cross talk will guide 
rational interventions in this common, 
often catastrophic, syndrome.
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Renin–angiotensin system 
blockade and diabetes:  
moving the adipose organ from 
the periphery to the center
Oliver Lenz1 and Alessia Fornoni1,2
Lee et al. report that an angiotensin II type 1 receptor blocker (ARB) 
improved glucose intolerance in OLETF rats, an experimental model of 
type 2 diabetes. ARB treatment resulted in modulation of the adipose 
tissue, leading to an increased number of small, differentiated adipocytes 
able to produce more adiponectin and less monocyte chemoattractant 
protein-1 and plasminogen activator inhibitor-1. This supports the 
relevance of the functional interplay between adipose tissue and the 
renin–angiotensin system in states of insulin resistance.
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A large body of literature suggests that 
renin–angiotensin system (RAS) block-
ade with either an angiotensin-converting 
enzyme inhibitor or an angiotensin recep-
tor blocker (ARB) will prevent new-onset 
type 2 diabetes.1 Two receptors for angio-
tensin II have been described in humans, 
the angiotensin II type 1 (AT1) and type 2 
(AT2) receptors. Among them, the AT1 
receptor seems to be primarily responsible 
for the metabolic effect of RAS blockade.2 
In fact, the AT1 and AT2 receptors may 
have antagonistic activities on glucose 
uptake and cell differentiation in adipose 
tissue, as suggested by studies performed 
in AT2-null mice.3 How RAS blockade 
leads to a diminished incidence of type 
2 diabetes remains to be fully elucidated. 
The following mechanisms are being 
investigated (Figure 1): upregulation of 
muscle glucose uptake via modulation 
of glucose transporter-4 (GLUT4) and 
blood flow;4 improvement of pancreatic 
β-cell function;5 modulation of hormonal 
responses from adipose tissue;2 decreased 
hepatic gluconeogenesis and increased 
free fatty acid oxidation;6 improvement 
of endothelial function through down-
regulation of NADPH oxidase;2 direct 
stimulation of insulin signaling at multi-
ple levels;7 and direct regulation of per-
oxisome proliferator-activated receptor-γ 
(PPARγ) by selected ARBs, such as tel-
misartan and irbesartan.8 Experimental 
data suggest that RAS-blocking agents 
that act on more than one pathway might 
be more effective for the prevention of 
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diabetes. However, a large clinical trial 
failed to show an advantage of telmisartan 
over ramipril, suggesting that the inherent 
agonistic action of telmisartan on PPARγ 
may have less clinical relevance than ini-
tially hypothesized.9
Recent investigations have focused 
on the cross-talk between adipose tis-
sue and organs affected by macrovascu-
lar and microvascular complications of 
diabetes. Among the various cytokine-
like hormones secreted by adipose 
tissue, also referred to as adipokines, 
adiponectin is the most abundant.10 
Adiponectin expression inversely cor-
relates with the development of insulin 
resistance and cardiovascular disease, 
and a polymorphism in the adiponectin 
promoter affecting gene expression has 
been linked to diabetes and its complica-
tions.11 Adiponectin-null mice develop 
severe proteinuria and podocyte damage, 
which can be reversed by the adminis-
tration of recombinant adiponectin, 
establishing a cause–effect relation 
between adiponectin and albuminuria, 
a marker of both insulin resistance and 
early diabetic nephropathy.12 Whether 
a similar mechanism may be at play 
in patients with diabetic nephropathy 
remains to be seen. It is possible that 
modulation of adiponectin production 
by RAS blockade may provide a unifying 
explanation for the metabolic, cardio-
vascular, and renal protection afforded 
by angiotensin-converting enzyme 
inhibitors and ARBs.
The work of Lee et al.13 (this issue) pro-
vides experimental evidence that treat-
ment with an ARB (L158809) is associated 
with a blood pressure−independent 
increase in small differentiated adipo-
cytes and increased adiponectin con-
centrations in the adipose tissue of a 
rat model of diabetes, the OLETF rat, 
consistent with a recent report in KK-Ay 
mice.2 Angiotensin II-induced oxidative 
stress and upregulation of plasmino-
gen activator inhibitor-1, monocyte 
chemo attractant protein-1, and nuclear 
factor-κB expression could be improved 
in vitro by treatment with an ARB, which 
coincided with increased adiponectin and 
PPARγ expression. The lack of changes 
in insulin and C-peptide concentration 
and insulin-resistive indices after ARB 
administration suggests that modula-
tion of adipokines or GLUT4 function 
represents the most likely mechanism 
by which ARBs improve glycemia in the 
described model.
Diabetes and its complications are 
associated with a chronic inflammatory 
state that directly correlates with the 
degree of insulin resistance and endothe-
lial dysfunction. In contrast, adiponectin 
inversely correlates with insulin resistance 
and has a wide range of anti-inflamma-
tory properties.10 In macrophages, adi-
ponectin reduces the transformation of 
macrophages to foam cells and suppresses 
the class A scavenger receptor; it reduces 
lipopolysaccharide-induced tumor necro-
sis factor-α expression; it reduces nuclear 
factor-κB activation; and it affects the 
expression of adhesion molecules respon-
sible for monocyte adhesion to endothe-
lial cells. In addition, adiponectin reduces 
the lipopolysaccharide-induced expres-
sion of several chemokines without affect-
ing their corresponding receptor CXCR3 
in macrophages. At the same time, adi-
ponectin does not suppress chemokine 
induction by interferon-γ; this supports 
the notion that adiponectin works via 
the Toll-like receptor-4 (TLR4) signaling 
pathway. This is very interesting, as TLR4 
has been implicated in the development 
of atherosclerosis, insulin resistance, and 
proteinuria. A more detailed characteri-
zation of the interaction among the hor-
monal response of the adipose organ in 
diabetes, adaptive immunity, and devel-
opment of insulin resistance may shed 
light on novel mechanisms responsible 
for the development of diabetes. Further 
studies are needed to determine to what 
extent the anti-inflammatory effects of 
RAS blockade and adiponectin share 
common pathways. The impact of such 
anti-inflammatory actions on the devel-
opment of type 2 diabetes also requires 
additional analysis, as a randomized 
clinical trial in a prediabetic population 
failed to show a benefit of ramipril over 
placebo to prevent new-onset type 2 dia-
betes.14 Additional insight may be gained 
by investigating downstream therapeutic 
targets, such as adiponectin per se, rather 
than focusing on the effect of widely used 
medications on the hormonal function 
of adipose tissue. In particular, a more 
figure 1 | Key functions of adipocytes in the pathogenesis of insulin resistance. Large 
dedifferentiated adipocytes characterize insulin-resistant states. Blockade of the renin–angiotensin 
system via either an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker 
(ARB) restores small, differentiated adipocytes via angiotensin II type 1 (AT1), AT2, and peroxisome 
proliferator-activated receptor-γ (PPARγ) receptors. Small, differentiated adipocytes produce less tumor 
necrosis factor-α (TNF-α), monocyte chemoattractant protein-1 (MCP-1), and plasminogen activator 
inhibitor-1 (PAI-1), and more adiponectin. Adiponectin affects glucose uptake and metabolism 
in skeletal muscle and liver, pancreatic β-cell function, endothelial function, and development of 
albuminuria. GLUT4, glucose transporter-4; IRS, insulin receptor substrate; NO, nitric oxide.
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detailed characterization of the pattern 
of distribution of adiponectin receptors 1 
and 2 is needed, as adiponectin receptors 
have been fully characterized solely in 
muscle, liver, kidney, and macrophages. 
Once the tissue distribution of adiponec-
tin receptors is known, the development 
of specific adiponectin receptor modula-
tors that can be orally administered and 
have a longer half-life than adiponectin 
may represent a novel treatment strategy 
for the prevention or cure of type 2 dia-
betes and its complications.
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